Yes. We offer a variety of common modifications, including but not limited to pseudo uridine (Ψ) or N1-methylpseudo uridine (m1Ψ) incorporation to reduce immunogenicity, custom cap analogs and custom poly(A) tail lengths. Please inquire during the quote design phase so we can propose the best strategy for your application.

Our mRNA experts have a long history of working with leading scientists on custom constructs and would be happy to discuss your unique application. Please contact with our sales team to customize your specific request.

Yes, all mRNA products undergo diversified purification processes to fulfil end-user application scenarios. After IVT (in vitro transcription), The reaction mixture is first treated with DNase I to degrade the DNA template, then the mRNA is selectively precipitated by LiCl or loaded onto the silica column to pass through the membrane to remove impurities and other reaction components. The mRNA is captured and further eluted by applying RNase-free water. The final mRNA is sterile-filtered before aliquoting.
In the case of scale-up production, the industrialized Oligo (dT) chromatography and TFF are used as advanced purification methods to precisely capture and polish Poly(A) tailed mRNA.

Based on high quality material/regent such as DNA plasmid and modified T7 polymerase enzyme, we employ an optimized IVT protocol, designed to reduce dsRNA formation. This approach significantly reduces dsRNA generation, helping to minimize nonspecific immune stimulation in cells and animals.

Our mRNA synthesis platform supports both co-transcriptional and enzymatic capping. For standard applications, we typically use high-performance Cap 1 analogs supplied by our partners, enhances translation efficiency and reduces immunogenicity.

Additionally, we provide a proprietary AG analog with FTO-guaranteed, licensing IP, available for licensing in clinical-stage and commercial mRNA therapeutic applications.

Depending on different preclinical stages, a phase-appropriate QC protocol is applied across the most crucial quality attributes like RNA length, concentration, purity (A260/A280), pH, and endotoxin. This ensures you receive a high-quality mRNA product suitable for your research needs.

For preclinical grade mRNA, we use automated capillary electrophoresis to accurately quantify the mRNA and evaluate its integrity. The results are documented in the Report of Analysis (RoA) provided with your mRNA product.

Absolutely. Although our service is intended solely for in vitro studies, the endotoxin levels in products exceeding research grade are still subject to quality control in compliance with the method outlined in USP<85>. Each individual batch is tested using the LAL gel-clot method and released with endotoxin levels below 10 EU/mg RNA, ensuring the reliability and consistency of research-grade quality.